Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) Return on Capital Employed (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Return on Capital Employed for 10 consecutive years, with 0.45% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Capital Employed fell 34.0% to 0.45% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.45%, a 34.0% decrease, with the full-year FY2025 number at 0.41%, down 28.0% from a year prior.
  • Return on Capital Employed was 0.45% for Q4 2025 at Cartesian Therapeutics, down from 0.25% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.2% in Q2 2022 to a low of 0.63% in Q4 2023.
  • A 5-year average of 0.2% and a median of 0.18% in 2021 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: surged 99bps in 2021, then crashed -74bps in 2023.
  • Cartesian Therapeutics' Return on Capital Employed stood at 0.05% in 2021, then soared by 296bps to 0.1% in 2022, then plummeted by -736bps to 0.63% in 2023, then surged by 83bps to 0.1% in 2024, then crashed by -332bps to 0.45% in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Return on Capital Employed are 0.45% (Q4 2025), 0.25% (Q3 2025), and 0.23% (Q2 2025).